MarketScreener Ratings

Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Vertex Pharmaceuticals Incorporated

Ratings ESG MSCI

Ratings ESG MSCI - Vertex Pharmaceuticals Incorporated

Ratings Vertex Pharmaceuticals Incorporated: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Vertex Pharmaceuticals Incorporated
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: Vertex Pharmaceuticals Incorporated
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • With an expected P/E ratio at 44.78 and 27.63 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Rating Financials

Vertex Pharmaceuticals Incorporated SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Vertex Pharmaceuticals Incorporated

Rating Valuation

Vertex Pharmaceuticals Incorporated SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Vertex Pharmaceuticals Incorporated

Rating Consensus

Vertex Pharmaceuticals Incorporated SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Vertex Pharmaceuticals Incorporated

Rating Business Predictability

Vertex Pharmaceuticals Incorporated SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Vertex Pharmaceuticals Incorporated

Rating Revisions

Vertex Pharmaceuticals Incorporated SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Vertex Pharmaceuticals Incorporated


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
123B
AA
1,040B
A
599B
BBB
485B
AAA
-
350B
AA
345B
AA
272B
AAA
244B
A
223B
BBB
183B
AA
Average 386.58B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. VRTX Stock
  4. Ratings Vertex Pharmaceuticals Incorporated